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Layman’s summary  
 
Metabonomics [1, 2], the measure of the fingerprint of biochemical perturbations caused by disease, 
drugs or toxins, recently has become a major focus of research in various areas [3] especially 
indications of drug toxicity [4-8]. Two types of technology (known by the initials NMR and MS) are 
employed and both produce massive data in form of spectra. Sophisticated statistical models, known as 
pattern recognition techniques, are commonly applied for summarizing and analysing these 
multidimensional data. However, strong signals from compounds that are administered during 
toxicological trials interfere with these models. So called “spectral replacement” [9] is a method to 
eliminate these signals by replacing them with the signals in their corresponding regions in control 
spectrum. The replaced regions are subsequently scaled. However, this scaling is not accurately 
measured and often results in overestimation of integrated intensity of the replaced signals. Here, a 
novel protocol is proposed which provides an accurate estimation of the replaced regions. 
 
Background 
 
Cells and tissues attempt to recover from ‘disease- or xenobiotic-induced’ disturbances of ratios, 
concentrations, and fluxes of chemicals and molecular species (metabolites) via dynamically 
modulating the biochemical composition of the body fluids through perfusion or secretion. Therefore, 
biofluids or tissue samples potentially contain a wealth of information regarding metabolic status 
(concentrations of various metabolites) of organisms and may be indicative of toxicity or disease 
conditions. For this reasons, metabonomics, defined as “quantitative measurement of time-related 
multi-parametric metabolic responses of multi-celluar systems to pathophysiological stimuli or genetic 
modification" [1, 2], recently has become a major focus of research in various areas [3] especially 
indications of drug toxicity [4-8]. Xenobiotics are compounds such as toxins or drugs that are not 
normally present in organisms or are at much lower levels before administration. Metabolites are small 
molecules, normally present in all organisms, and are essential to the functioning of their living cells. 
Metabonomics originates from metabolite profiling [10], which initially appeared in literature in 1950s 
[7]. Metabonomics employs two specific types of technology i.e. NMR and MS, which are 
sophisticated procedures to measure concentrations of compounds in samples and both produce a large 
amount of data in form of spectra. Each spectrum contains massive information about the profiles of 
metabolites and xenobiotics (if present). In Figure 1 there are five different NMR spectra of urine 
samples taken from five rats, which four of them received different treatments and one of them (at the 
bottom) did not (control). Red arrows indicate strong signals from administered xenobiotics (drugs).  
 
For the rest of the text, spectra of samples from organisms subjected to xenobiotic treatments are 
referred to as ‘test spectra’ and those without treatment as ‘control spectra’. Also, those regions of test 
spectrum in which the drug metabolite signals appear are referred to as C regions (see Figure 2(6)) and 
their corresponding regions in control spectra as c . Similarly, regions of indigenous metabolite signals 
in test spectrum referred to as B (see Figure 2(3)) and their corresponding regions in control asb . The 
rest of test spectrum (without C and B ) is referred to as A (see Figure 2(2)) and their corresponding 
regions in control as a . Figure 2 illustrates two simple computationally simulated spectra (test and 
control shown by red and black lines, respectively). Two simulated spectra are superimposed and 
therefore the control spectrum (black line) is visible only in those regions wherein two spectra do not 
overlap i.e. B (or b ) regions. 
 
Expert systems capable of predicting the likelihood of the toxicity of novel drug candidates have been 
developed employing series of mathematical models. Pattern recognition techniques such as principle 
component analysis (PCA) [11] are widely used for summarising these multidimensional data. PCA 
captures and displays the most dominant patterns in the data matrix. However, xenobiotic compounds 
administered during toxicological trials to the organisms often generate strong signals, which interfere 
with these mathematical models, presenting themselves as the most dominant patterns.  
 
Figure 1 Five NMR spectra of urine samples from rats which four of them received different 
treatments and the last one (at the bottom) did not receive any treatment. Strong signals from 
administered xenobiotics are indicated with red arrows 
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Figure 2 Two simple simulated test and control spectra 
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Since most of xenobiotic metabolites and their spectral regions (i.e. C regions) are well known, it 
would have been possible to simply excise all these regions if there were a small number of toxins in a 
database with a scarce number of xenobiotic-related peaks. When one region is excised, all 
corresponding spectral regions of the excised part in all other spectra must also be excised so as to keep 
them comparable. This can pose a major problem for large databases such as the COMET[12, 13] 
project containing wide range of model toxins. In these situations, almost all of the spectral regions 
might have to be eliminated (See Figure 1). Other procedures like replacing these regions with zero or 
mean values are not optimum alternative when there are large numbers of spectra. Thus, it is necessary 
to somehow estimate the ‘increased integrated intensity’ of signals in C regions, which are ‘added’ 
purely due to presence of administered xenobiotics (See Figure 2 (4)). So called “spectral replacement” 
[9] is a method which has been developed for this purpose and applied in a number of studies [14-16].  
 
Scientific methodology  
 
As mentioned earlier, strong signals of the administered xenobiotics obscure signatures of indigenous 
metabolic changes which are characteristics of organisms’ responses to the xenobiotics. Spectral 
replacement is a bioinformatics solution to eliminate xenobiotic signals by replacing them with their 
corresponding regions in control spectrum.  In other words, C regions of test spectrum is replaced with 
corresponding c region from control spectrum. The inserted c region in test spectrum is scaled by a 
factor, f, using Equation 1 so as to have the same fraction of the total integrated intensity of test 
spectrum as it did in said control spectrum Figure 2 (5). Since in this method, the fraction of integrated 
intensity of replaced c regions to total integral intensity of the test spectrum is estimated based on their 
fraction to total integral intensity of control spectrum, the influence of the significant changes of 
indigenous metabolites (as result of toxic reaction) on total integrated intensity of test spectrum is not  
taken into account. This leads to inaccurate estimation (most likely overestimation) of integrated 
intensity of replaced signals, see Figure 2 (4, 5). The novel protocol proposed here provides an accurate 
estimation of integrated intensity of replaced signals in test spectrum; see Figure 2(1, 7).  Figure 2 
schematically illustrates two superimposed test and control spectra, red and black lines, respectively. 
Turquoise and green lines represent estimated integrated intensities of the replaced signals in C region 
using spectral replacement and the novel method, respectively.  
 
Equation 1 extracted from spectral replacement[9] 
wherein:
IY is the total integrated intensity of the test spectrum; 
IY,Tk is the integrated intensity of the target (i.e. C) region;
ICM is the total integrated intensity of the control spectrum; 
ICM,Rk is the integrated intensity of the replacement region i.e. c region; 
k ranges from 1 to nt; and,
nt is number of target (i.e. C) regions.
f = 
IY - 
ICM -
__________
Σ IY,Tk
k
Σ ICM,Rk
k
 
 
To simplify comparison, in this simulation it is assumed that the test and the control spectra are from 
two samples with identical molar concentrations, therefore, ideally the estimated integrated intensity of 
signals in C region of the test spectrum must have the same integrated intensity of c region of the 
control spectrum, i.e. the green and the black lines should overlap (see Figure 2 (1, 6, 7)). According to 
biological assumptions, kaA = and IKbB += , where I is the amount of changes of integrated 
intensity of B regions after xenobiotics administeration and k is a scaling factor reflecting difference 
between concentrations of the biofluid samples. Similarly, DKcC += , where D is the ‘added’ 
intensity of signals in C region resulting from the presence of administered xenobiotics. Therefore, test 
(Test ) and control ( Ctrl ) spectra can be defined as:  
cbaCtrl ++=  and DkcIkbkaTest ++++=  
If the replacement and scaling measure is carried out correctly, the ideal spectrum, Goal , should be a 
specific version of test spectrum in which D (see Figure 2(4)), has been subtracted from integrated 
intensity of the C regions, while I integrated intensity retained in B regions. Therefore:  
IkckbkaGoal +++=  or )( icbakGoal +++=  
The Goal spectrum can be calculated via the following proposed four-step protocol:  
STEP I: C and c regions are removed from test and control spectra respectively.   
                           baCtrlSTEPI +=  and kikbkaTestSTEPI ++=  
STEP II: b regions of the step 1 control spectrum are replaced with the corresponding B regions of the 
step 1 test spectrum. Each replaced region is scaled to a factor of F1 using Equation 1 so as to have the 
same fraction to the total integrated intensity of the step 1 control spectrum (i.e. after removal 
of c regions) as it did it in the step 1 test spectrum (i.e. after removal of C regions).  
Thus ))((1 ibkFaCtrlSTEPII ++=  
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The rearrangement of this equation gives 
K
F 11 =  ⇒ ibaCtrlSTEPII ++=  
STEP III: Deleted c regions are returned to control spectrum cibaCtrlSTEPIII +++=   
STEP IV: Deleted c regions of the control spectrum are inserted into the sample spectrum in place of 
deleted corresponding C regions. Inserted c regions are scaled to a factor of F2 using Equation 1 so as 
to have same fraction of total integrated intensity of test spectrum as they did in step 3 control spectrum  
cFibakTestSTEPIV 2)( +++=  
According to Equation 1, we know 
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Thus: GoalcibakTest STEPIV =+++= )(  
 
The main objectives of this project are:     
• Development of bioinformatics tool for implementation of the novel protocol for properly 
eliminating strong signals of xenobiotics from spectrum  
• Comparing the results from both simulated and biological data to estimate the 
performance of the software and the protocol in 'real world' applications  
o A procedure will be developed to compare the effect of implementation of the 
new protocol, spectral replacement, and other techniques such as zero-filling and 
mean value-filling on the results of pattern recognition models and techniques 
such as PCA using both simulated and biological data 
 
Timeliness and novelty  
 
Research and development cost of new drugs continues to rise above general price inflation while 
approval rates fall [17]. Efficient and reliable experimental / analytical chemistry approaches to 
eliminate xenobiotic metabolites are yet to be developed. Application of experimental methodologies 
such as labelling (fluorescent or radioactive) and NMR-HPLC techniques for this purpose can be time 
consuming and expensive with excessive bio- and radioactive hazards to environment as well as 
increased use of animals in experiments which raises ethical concerns. Fluorescence labelling may 
interact with xenobiotics. In those circumstances where xenobiotics normally exits in organism at 
lower levels before administration, even combination of radiolabelling and HPLC-NMR techniques 
also cannot separate co-eluting radiolabelled/organism’s xenobiotics. By contrast, bioinformatics 
approach proposed here, backed with mathematical proof, provides a cheap, rational, and relatively 
quick solution to eliminate the problem of strong xenobiotic signals. This protocol could be applied to 
other similar areas of data analysis. This project could also be viewed as is a measure of rectifying the 
inaccuracy of spectral replacement method, which has already been applied in a number of major 
metabonomic studies. Therefore this protocol could potentially play a major role in analysis and 
modelling of NMR and other forms of spectral data. The product of this project and the novel protocol 
itself could be potentially patentable.  
 
Programme of work  
 
This is a short term project and the following tasks are expected to be accomplished during 6 months 
period (Simulations will be performed within Matlab environment, Data from COMET project [12] as 
well as publicly available databases will be used): 
 
Months 1 2 3 4 5 6 
Software development            
Data modelling /Simulation          
Data analysis           
Preparing report        
 
 
Justification of resources    
 
• Principle investigator: 6 months graduate student / research assistant 
• Desktop PC (a platform for developing software and data analysis, and preparing final report) 
• Software Licenses, including Matlab, SIMCA-P and NMR processing software 
• Consumables - Stationery, photocopying charges, toner library charges, etc 
 
Beneficiaries  
 
Aiming to resolve one of the major confounding factors in modelling of data from metabonomic 
spectra, this small project potentially has a wide range of beneficiaries including 
• The growing metabonomic community who analyse NMR and other types of spectra 
• Scientists involved in developing or using databases of NMR or other types of spectra 
• With expansion of metabonomic applications such as pharmaco-metabonomics, nutritional-
metabonomics system biology, involved scientists such as system biology scientists will have 
more accurate information, as the result of this project, to integrate in holistic modelling of 
fundamental biological processes  
• Pharmaceuticals, food and agriculture industries, those involved in toxicological studies and 
those for which understanding and monitoring metabolic activity and quality control of drugs 
or food is essential, Researchers involved in preclinical and clinical toxicological screening as 
well as those involved in designing personalised treatments, or diets 
Because the project increases the better use of existing information and also improves the use of 
metabolic profiling in screening procedures, it will indirectly contribute to the reduced use of animals 
in biological research and also reduced bio and radioactive hazards to environment 
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